The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab  

作　　者：Sabine Lieb Sebastian Ebel Daniel Seehofer Thomas Berg Florian van Bommel 

机构地区：[1]Division of Hepatology,Department of Medicine II,Leipzig University Medical Center,Leipzig,Germany [2]Department of Diagnostic and Interventional Radiology,Leipzig University Medical Center,Leipzig,Germany [3]Department of Visceral,Vascular,Thoracic and Transplant Surgery,Leipzig University Medical Center,Leipzig,Germany

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第1期148-150,共3页肝胆外科与营养（英文）

摘　　要：With great interest we have read the comment of Dr.Khakoo on the recently published CRAFITY score for the prediction of response to anti-programmed death(ligand)1[PD-(L)1]-based immunotherapy in patients with unresectable hepatocellular carcinoma(HCC)(1).

关 键 词：PATIENTS HEPATOCELLULAR carcinoma 

分 类 号：R735.7[医药卫生—肿瘤]